HLA-E and Hodgkins lymphoma: In EBV+HL (Figures 2C) and EBV+nHL (Figures 2D, S2) patients, the HLA-E*0103/0103 variant dominated, however, while patients encoding for the HLA-E*0101 allele were, in comparison to asymptomatic patients (EBV+HL: p<0.0001, OR: 7.3 (95% CI: 2.7-19.6); EBV+nHL: p<0.0001, OR: 6.1 (95% CI: 2.7-14), Fisher’s-test) and symptomatic patients (EBV+HL: p<0.0001, OR: 19.9 (95% CI: 6.8-58.3); EBV+nHL: p<0.0001, OR: 16.8 (95% CI: 6.6-42.4), Fisher’s-test) significantly underrepresented.